List Title | APhA DrugInfoLine

Cardiology

SORT BY: Most Recent Most Viewed

January 7, 2019

Reduction in heart failure associated with dapagliflozin use

READ

PREVIEW
Use of dapagliflozin (Farxiga—AstraZeneca) in patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular (CV) disease resulted in a significant reduction in the risk...
January 7, 2019

Cardiovascular events are lower with statins plus alirocumab

READ

PREVIEW
Adding alirocumab (Praluent—Sanofi, Regeneron) to high-intensity statin therapy for patients who had an acute coronary syndrome (ACS) in the preceding 12 months resulted in a significantly lower...
December 26, 2018

New lipid guideline emphasizes personalized decision making

READ

PREVIEW
The American College of Cardiology (ACC) and American Heart Association (AHA) task force released an updated guideline on management of high cholesterol. The guideline has a greater focus on...
November 20, 2018

Reassessing use of statins for primary prevention in older adults

READ

PREVIEW
In people older than age 74 years without diabetes, statin use for primary prevention was not associated with a reduction in the risk of atherosclerotic cardiovascular (CV) disease or all-cause...
November 6, 2018

A bleak picture of aspirin for primary prevention in older adults

READ

PREVIEW
Three publications in the New England Journal of Medicine from the ASPREE trial showed that daily use of low-dose aspirin in healthy, community-dwelling older people without documented...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.